Loading data for HOWL — first visit, this takes a few seconds.

알림

Werewolf Therapeutics Inc... (HOWL)

NasdaqCM: HOWL · 실시간 가격 · USD

0.41

+0.00 (0.00%)

종가 기준: Aug 19, 2026, 4:14 PM

0.00% (1D)

데이터 없음

매수호가	0.29
시가총액	20.02M
매출 (ttm)	21M
순이익 (ttm)	-34.61M
베타	0.29
EPS (ttm)	-0.73
P/E (ttm)	n/a
선행 P/E	-0.42
P/B (ttm)	1.23
P/S (ttm)	0.95
Earnings Date	Oct 30, 2026

매도호가	0.53
거래량	58,525
평균 거래량 (20일)	706,629
시가	0.41
전일 종가	0.41
일중 범위	0.40 - 0.42
52주 범위	0.27 - 2.38
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

HOWL 소개

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Apr 30, 2021

직원 수 39

상장 거래소 NasdaqCM

티커 HOWL

웹사이트 https://werewolftx.com

전체 기업 정보

재무 실적

2025년 Werewolf Therapeutics의 매출은 0로, 전년 1.89M 대비 -100% 감소했습니다. 순이익은 -60.82M로, -13.75% 감소했습니다.

재무제표

어닝 서프라이즈

Werewolf Therapeutics가 Jul 31, 2026에 분기 실적을 발표했습니다:

매출 $21M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.

EPS 0.14 예상치 상회 0.46, 및 135.00% 전년 대비 성장.

다음 실적 발표

Werewolf Therapeutics Inc.의 실적 발표 예정일은 Oct 30, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Zacks

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

3개월 전 · Simply Wall St.

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

7개월 전 · Insider Monkey

Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline ...

8개월 전 · Zacks

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9개월 전 · Zacks

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.

2 페이지 중 1

Werewolf Therapeutics Inc... (HOWL)